Zobrazeno 1 - 10
of 727
pro vyhledávání: '"W, Mier"'
Autor:
Bob T. Li, David M. Hyman, Dean J. Welsch, Mary Varterasian, Saurabh Saha, Anna L. Groover, Caroline M. Emery, Gary A. DeCrescenzo, Sapna P. Patel, Antoni Ribas, Mario E. Lacouture, Anna M. Varghese, Richard D. Carvajal, Elizabeth Buchbinder, Keith Flaherty, Mario Sznol, Andrea Wang-Gillam, Anthony W. Tolcher, James W. Mier, Geoffrey I. Shapiro, Manish R. Patel, Vicki Keedy, Jeffrey A. Sosman, Deborah Jean Lee Wong, Filip Janku, Jeffrey R. Infante, Ryan J. Sullivan
Tumor types and molecular alterations of enrolled patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7056746bff2432eadfcb1840e1a0b9f9
https://doi.org/10.1158/2159-8290.22532095.v1
https://doi.org/10.1158/2159-8290.22532095.v1
Autor:
Ryan J. Sullivan, James W. Mier, Keith T. Flaherty, A. John Iafrate, Michael B. Atkins, Dennie Fredrick, Anasuya Gunturi, F. Stephen Hodi, Virginia J. Seery, Ryan Merritt, Jennifer A. Wargo, Alexander Carlson, Rachel Cohen, David F. McDermott, Donald P. Lawrence, Alireza Sepehr, Laleh Montaser-Kouhsari, Aislyn P. Schalck, Anita Giobbie-Hurder, Elizabeth Buchbinder, David J. Panka
BRAF inhibitors (BRAFi) have led to clinical benefit in patients with melanoma. The development of a blood-based assay to detect and quantify BRAF levels in these patients has diagnostic, prognostic, and predictive capabilities that could guide treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e4fef1a26720d8b3344d7e0a2a2f162
https://doi.org/10.1158/1535-7163.c.6536487
https://doi.org/10.1158/1535-7163.c.6536487
Autor:
Ryan J. Sullivan, James W. Mier, Keith T. Flaherty, A. John Iafrate, Michael B. Atkins, Dennie Fredrick, Anasuya Gunturi, F. Stephen Hodi, Virginia J. Seery, Ryan Merritt, Jennifer A. Wargo, Alexander Carlson, Rachel Cohen, David F. McDermott, Donald P. Lawrence, Alireza Sepehr, Laleh Montaser-Kouhsari, Aislyn P. Schalck, Anita Giobbie-Hurder, Elizabeth Buchbinder, David J. Panka
Supplemental Figure Legends from Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a0765140c494df0970dead7a9b648c5
https://doi.org/10.1158/1535-7163.22500519.v1
https://doi.org/10.1158/1535-7163.22500519.v1
Autor:
Ryan J. Sullivan, James W. Mier, Keith T. Flaherty, A. John Iafrate, Michael B. Atkins, Dennie Fredrick, Anasuya Gunturi, F. Stephen Hodi, Virginia J. Seery, Ryan Merritt, Jennifer A. Wargo, Alexander Carlson, Rachel Cohen, David F. McDermott, Donald P. Lawrence, Alireza Sepehr, Laleh Montaser-Kouhsari, Aislyn P. Schalck, Anita Giobbie-Hurder, Elizabeth Buchbinder, David J. Panka
BRAFV600E levels in patients with detectable BRAFV600E mutation in tissue who had peripheral blood cell isolation using CPT tubes vs Ficoll.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35cde1f5f1c23bee3093a7038029031c
https://doi.org/10.1158/1535-7163.22500525.v1
https://doi.org/10.1158/1535-7163.22500525.v1
Publikováno v:
Molecular Cancer, Vol 20, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/d1148a1c84c347f38f7fd62368cbf081
Publikováno v:
Molecular Cancer, Vol 20, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/c86aa56e159849feb00c6e53aa55c18c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Paul M. Sondel, David F. McDermott, David J. Panka, James W. Mier, Alexander Carlson, Michael Atkins, Sabina Signoretti, Su-Chun Cheng, Jacquelyn A. Hank, Yiqiang Song, Eneida A. Mendonca, Dustin Hess, Lakeesha Carmichael, KyungMann Kim, Mikayla Gallenberger, Jacob Goldberg, Wei Wang, Amy K. Erbe
Supplementary Table 1. Frequency of FCGR genotypes and HWE test. Supplementary Table 2. PFS Clinical Outcome Assessment of FCGR2A, FCGR3A and FCGR2C SNPs. Supplementary Table 3. Clinical Outcome Parameters were Assessed for FCGR3A, FCGR2A and FCGR2C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c31e34d0151b1a1caf20178c8b01c44
https://doi.org/10.1158/1078-0432.22465214
https://doi.org/10.1158/1078-0432.22465214
Autor:
Rupal S. Bhatt, Roger A. Sabbadini, Manoj Bhasin, Sabina Signoretti, James W. Mier, Michael B. Atkins, David C. Alsop, Douglas Deutschman, Barbara Visentin, Kelli Moreno, Jiaxi Song, Harleen Shah, Marcella Callea, Andrea J. Bullock, Xiaoen Wang, Liang Zhang
Table S1: Plasma S1P levels in patients with RCC; Table S2: Table of ASL MRI values.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::679cd8fd847d704422c517b1d333c8f7
https://doi.org/10.1158/1078-0432.22456143.v1
https://doi.org/10.1158/1078-0432.22456143.v1
Autor:
Rupal S. Bhatt, Roger A. Sabbadini, Manoj Bhasin, Sabina Signoretti, James W. Mier, Michael B. Atkins, David C. Alsop, Douglas Deutschman, Barbara Visentin, Kelli Moreno, Jiaxi Song, Harleen Shah, Marcella Callea, Andrea J. Bullock, Xiaoen Wang, Liang Zhang
Purpose: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic renal cell carcinoma (RCC). However, resistance to treatment is inevitable. Identification of novel targets could lead to better treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20cf7ff807f52d401d37aa642d876bc8
https://doi.org/10.1158/1078-0432.c.6523218
https://doi.org/10.1158/1078-0432.c.6523218